Bisphosphonate Therapy in Hyperparathyroidism
Clinical Guidelines and Recommendations
- The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest not prescribing bisphosphonate treatment in people with GFR <30 ml/min/1.73 m² (CKD G4-G5) without a strong clinical rationale, and the American Journal of Kidney Diseases recommends caution when using bisphosphonates in patients with hyperparathyroidism 1, 3
- The American College of Rheumatology, as reported in Arthritis care & research, recommends evaluating bone health, including the presence of osteoporosis or osteopenia, history of fragility fractures, and risk factors for fractures, before considering bisphosphonate therapy in patients with hyperparathyroidism 2
Patient Evaluation and Monitoring
- Patients with hyperparathyroidism should be carefully evaluated, including assessment of renal function, before bisphosphonate therapy is initiated, and should be monitored regularly for serum calcium, phosphate, and parathyroid hormone (PTH) levels 1, 3
- The Kidney International guidelines recommend ensuring normal renal function (eGFR >30 ml/min/1.73m²) before initiating bisphosphonate therapy in patients with hyperparathyroidism 3